Chiesi signs $1.9B deal to acquire KalVista and its approved drug

April 29, 2026 09:25 AM EDT DealsPharma Chiesi signs $1.9B deal to ac­quire KalVista and its ap­proved drug Kyle LaHucik Biotech Correspondent Chiesi is buy­ing com­mer­cial biotech KalVista Phar­ma­ceu­ti­cals for about $1.9 bil­lion in an ex­ten­sion of the in­dus­try’s vig­or­ous spring shop­ping spree. The Ital­ian phar­ma will … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER